Browse

You are looking at 111 - 120 of 3,909 items for

  • Refine by Access: Content accessible to Me x
Clear All
Full access
Full access

Leslie A. Fecher, Shrinivas Bishu, Robert J. Fontana, Salim S. Hayek, and Bryan J. Schneider

Immune checkpoint inhibitors have revolutionized the treatment of cancer and are now omnipresent. However, immune-related adverse events can present with varying phenotypes and timing, which can pose diagnostic and therapeutic challenges for the treating oncologist as well as subspecialty consultants. Biopsies of affected organs may provide insight into biologic mechanisms as well as potentially guide management in certain circumstances.

Full access

Kathryn P. Lowry, Katherine A. Callaway, Janie M. Lee, Fang Zhang, Dennis Ross-Degnan, J. Frank Wharam, Karla Kerlikowske, Karen J. Wernli, Allison W. Kurian, Louise M. Henderson, and Natasha K. Stout

Background: Annual mammography is recommended for breast cancer survivors; however, population-level temporal trends in surveillance mammography participation have not been described. Our objective was to characterize trends in annual surveillance mammography participation among women with a personal history of breast cancer over a 13-year period. Methods: We examined annual surveillance mammography participation from 2004 to 2016 in a nationwide sample of commercially insured women with prior breast cancer. Rates were stratified by age group (40–49 vs 50–64 years), visit with a surgical/oncology specialist or primary care provider within the prior year, and sociodemographic characteristics. Joinpoint models were used to estimate annual percentage changes (APCs) in participation during the study period. Results: Among 141,672 women, mammography rates declined from 74.1% in 2004 to 67.1% in 2016. Rates were stable from 2004 to 2009 (APC, 0.1%; 95% CI, −0.5% to 0.8%) but declined 1.5% annually from 2009 to 2016 (95% CI, −1.9% to −1.1%). For women aged 40 to 49 years, rates declined 2.8% annually (95% CI, −3.4% to −2.1%) after 2009 versus 1.4% annually in women aged 50 to 64 years (95% CI, −1.9% to −1.0%). Similar trends were observed in women who had seen a surgeon/oncologist (APC, −1.7%; 95% CI, −2.1% to −1.4%) or a primary care provider (APC, −1.6%; 95% CI, −2.1% to −1.2%) in the prior year. Conclusions: Surveillance mammography participation among breast cancer survivors declined from 2009 to 2016, most notably among women aged 40 to 49 years. These findings highlight a need for focused efforts to improve adherence to surveillance and prevent delays in detection of breast cancer recurrence and second cancers.

Full access

Leah Anton, Lauren Gallegos, and Chaitra Swain Simpson

Full access

Hemant Kumar Joon,, Anamika Thalor,, and Dinesh Gupta

Full access

John C. Ruckdeschel, Sriram Parasarathy, and Chiny Driscoll

Full access

Zhibo Tan, Min Chen, Feng Peng, Pengfei Yang, Zhaoming Peng, Xin Li, Xiaopeng Zhu, Yujie Zhao, and Yajie Liu